Form 4: Perceptive Advisors Reduces Stake in Acrivon Therapeutics

Perceptive Advisors LLC, along with related entities, sold shares of Acrivon Therapeutics (ACRV) at weighted average prices of $1.41 and $1.34, reducing their holdings.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman reported changes in their beneficial ownership of Acrivon Therapeutics, Inc. (ACRV) common stock.
• On April 30, 2025, they sold 437,881 shares at a weighted average price of $1.41, with prices ranging from $1.40 to $1.53.
• On May 1, 2025, they sold 298,886 shares at a weighted average price of $1.34, with prices ranging from $1.33 to $1.39.
• Following these transactions, Perceptive Life Sciences Master Fund Ltd. indirectly holds 3,104,139 shares.
• Joseph Edelman, as managing member of Perceptive Advisors LLC, disclaims beneficial ownership of these securities except to the extent of his indirect pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in holdings by a major shareholder, which could indicate a lack of confidence or a shift in investment strategy.

Negatives

• Perceptive Advisors reduced its stake in Acrivon Therapeutics, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from major shareholders like Perceptive Advisors could negatively impact ACRV's stock price.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a reduction in Perceptive Advisors' stake in Acrivon Therapeutics.

Stakeholder Impact

• Shareholders may react to the reduced stake by Perceptive Advisors, potentially leading to price volatility.
• The company may need to address investor concerns regarding the reasons for the sale.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Perceptive Advisors, Joseph Edelman, share sale, beneficial ownership, Form 4